Table 2. Comparative findings of outcomes for series describing over 20 taTME cases.
| Lacy et al 90 | Veltcamp Helbach et al 93 | Tuech et al 94 | Burke et al 95 | Chen et al 96 | Buchs et al 97 | |
|---|---|---|---|---|---|---|
| Study period | 10/2011–11/2014 | 6/2012–9/2014 | 2/2010–9/2014 | 3/2010–7/2015 | 12/2013–4/2015 | 5/2013–5/2015 |
| Study location | Barcelona, Spain | Amsterdam, the Netherlands | Rouen, France | Orlando, United States | Taipei, Taiwan | Oxford, United Kingdom |
| Number of institutions | 1 | 2 | 3 | 1 | 2 | 2 |
| Transanal device used | GelPOINT | GelPOINT or SILS | GelPOINT or endorec or SILS | GelPOINT | GelPOINT | GelPOINT |
| Total number of patients | 140 | 80 | 56 | 50 | 50 | 40 |
| Patient and tumor characteristics | ||||||
| Male gender, n (%) | 89 (64) | 48 (60) | 41 (73) | 30 (60) | 38 (76) | 32 (80) |
| Age, mean ± SD or median (range), y | 65.5 ± 12.7 | 65.3 ± 2.7 | 63 ± 2.7 | 57 ± 1.6 | 57.3 ± 11.9 | 64.4 ± 10.2 |
| Body mass index, mean ± SD or median (range), kg/m 2 | 25.2 ± 3.9 | 28.6 ± 1.8 | 29.0 ± 1.9 | 26.5 ± 1.2 | 24.2 ± 3.7 | 27.4 ± 4.9 |
| Tumor height, mean ± SD or median (range), cm | From AV 7.6 ± 3.6 |
From ARJ 5.3 (1–10) |
From AV 4 (0–5) |
From AV 4.4 (3.0–5.5) |
From AV 5.8 ± 2.1 |
From ARJ 3 (0–10) |
| Preoperative stage, n (%) | ||||||
| T1–2 | 29 (21) | All T2–T3 | 10 (18) | 7 (14) | – | Reported as ≥T3 |
| T3 | 90 (64) | 44 (79) | 35 (70) | 20 (40) | 23 (58) | |
| T4 | 11 (8) | 2 (4) | 8 (16) | 30 (60) | ||
| Neoadjuvant therapy, n (%) | 94 (67) | 65 (81) | 47 (84) | 43 (86) | 50 (100) | 12 (30) |
| Clinical outcomes | ||||||
| Total operative time, mean ± SD or median (range), min | 166 (60–360) | 204 (91–447) | 270 (150–495) | 267 (227–331) | 182.1 ± 55.4 | 368 ± 101.7 |
| Conversions, n (%) | 0 | – | 3 (7) | 1 (2) | 1 (2) | 3 (8) |
| Overall morbidity at 28 d, n (%) | 48 (34) | 31 (39) | 15 (26) | 18 (36) | 13 (26) | 16 (40) |
| Overall mortality at 28 d, n (%) | 0 | 1 (1) | 0 | 0 | 0 | 0 |
| Anastomotic leak, % | 12 (9) | – | 3 (5) | 3 (6) | 3 (6) | 1 (3) |
| Unplanned reoperation, % | 12 (9) | 9 (11) | – | 6 (12) | 2 (4) | 3 (8) |
| Length of hospital stay, mean ± SD or median (range), d | 6 (3–39) | 8 (3–41) | 10 (6–21) | 4.5 (4–8) | 7.4 ± 2.5 | 7 (3–92) |
| Pathological outcomes | ||||||
| Positive CRM, n (%) | 9 (6) | 2 (3) a | 3 (5) | 2 (4) | 2 (4) | 2 (5) |
| Positive DRM, n (%) | 0 | 0 | 0 | 1 (2) | 0 | 0 |
| TME quality, n (%) | ||||||
| Complete | 136 (97) | 71 (89) | 47 (84) | 36 (72) | – | 37 (93) |
| Moderate/near-complete | 3 (2) | 7 (9) | 9 (16) | 13 (26) | – | 2 (5) |
| Incomplete | 1 (1) | 2 (3) | 0 | 1 (2) | – | 1 (3) |
| Number of lymph nodes, mean ± SD or median (range) | 14.7 ± 6.8 | 16 ± 2 | 15 ± 1.9 | 18 ± 1.4 | 16.7 ± 7.8 | 20 ± 9.7 |
| Median follow-up, mo | 15 | 21 | 29 | 15 | – | 11 |
| Recurrence rate, n (%) | ||||||
| Local | 1 (1) | 2 (3) | 1 (2) | 2 (4) | – | – |
| Distant | 8 (6) | – | – | 7 (15) | – | 6 (15.0) |
| Both local and distant | 2 (2) | – | – | – | – | – |